Pfizer to Ask for Approval for RSV Vaccine for People as Young as 18

On April 9, Pfizer announced that it would request approval for its respiratory syncytial virus ( RSV ) vaccine for people as young as 18 years old.
According to the pharmaceutical company, data from an ongoing phase 3 trial revealed that the vaccine caused an immune reaction in people who were thought to be at risk for serious illness as a result of RSV, related to that seen in people 65 and older. The former group has now received approval for the vaccine in the United States.
Based on the results, Pfizer will ask the U. S. Food and Drug Administration ( FDA ) for expanded approval for the vaccine.
According to Dr. Iona Munjal, executive director of clinical vaccine research and development at Pfizer,” This represents a real opportunity for an expansion to an age population in a risk population that would n’t normally see the availability of this vaccine so soon.”

Source credit